Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
IL-35 (human):Fc (human) (rec.)
290
CHF
CHF 290.00
In stock
CHI-HF-21035-C02525 µgCHF 290.00
| Product Details | |
|---|---|
| Synonyms | Interleukin-35 |
| Product Type | Protein |
| Properties | |
| Source/Host | CHO cells |
| Sequence |
The human IL-35 complex composed of the Ebi3 subunit (aa 21-229) and the IL-12a (p35) subunit (aa 57-253) is fused through a polypeptide linker to the Fc portion of human IgG1. |
| Crossreactivity | Human |
| Biological Activity |
Bioactivity was measured in a cell proliferation assay using anti-CD3 activated human peripheral mononuclear cells. |
| Purity | ≥98% (SDS-PAGE) |
| Endotoxin Content | <0.06EU/μg protein (LAL test; Lonza). |
| Reconstitution | Reconstitute at 100μg/ml in sterile PBS. |
| Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
| Protein Negative Control | |
| Other Product Data |
NCBI reference NP_005746.2: Ebi3 subunit (human) |
| Declaration | Manufactured by Chimerigen. |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
| Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy.
Product References
- EBI3 downregulation contributes to type I collagen overexpression in scleroderma skin: H. Kudo, et al.; J. Immunol. 195, 3565 (2015)
- A potential immunopathogenic role for reduced IL-35 expression in allergic asthma: W. Wang, et al.; J. Asthma 52, 763 (2015)
- Anti-inflammatory roles of interleukin-35 in the pathogenesis of Japanese cedar pollinosis: H. Kouzaki, et al.; Asia Pac. Allergy 11, e34 (2021)
Related Products
